Compared to other enzyme families such as cytochromes P450, pharmacogenetic studies of human sulfotransferases (SULTs) in relation to drug response are fairly limited. Previously, human platelets have ...

From the perspective of current and future patients, the development of the field of pharmacogenetics is of immense interest. The encouraging vision that is now being ...

There's a new way to personalize drug therapy. It's pharmacogenetics - using information on genetic differences to tailor treatment. Deanna Kroetz, PhD, of UCSF's School of Pharmacy is exploring ...

Consumer genetics company 23andMe on Wednesday became the first to secure Food and Drug Administration (FDA) approval for a report that provides information about how a person’s genetics may impact ...

John Hwa is a professor of medicine and the director of cardiovascular pharmacogenetics at Yale School of Medicine. Along with Dartmouth genetics professor Jason H. Moore, Hwa recently coauthored an ...

For decades, genotyping has promised to serve as a practical means of relating genetic make-up and pharmacological efficiency—first at the level of patient groups and more recently at the level of ...

Please provide your email address to receive an email when new articles are posted on . Patients with AML who had a low ACS10 genetics score had worse survival outcomes than those with a high score.

Technical hurdles to the wide-spread use of genetic data in humans are disappearing. The cost of sequencing an entire human genome is sinking to around $1,000. Commercial companies are offering ...

Mutational Signature and Transcriptomic Classification Analyses as the Decisive Diagnostic Tools for a Cancer of Unknown Primary The Michigan Oncology Sequencing (MI-Oncoseq) program at The University ...

Combinatorial pharmacogenetics-guided treatment did not demonstrate improved outcomes compared to treatment-as-usual in adolescents with depression, and future research should examine specific ...

Hedgecoe and Martin invest a great deal of energy in imposing a superficial structure on the technological development within pharmacogenetics. They claim that there are two 'visions' guiding the ...